Cargando…
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patient...
Autores principales: | Morris, John C., Tan, Antoinette R., Olencki, Thomas E., Shapiro, Geoffrey I., Dezube, Bruce J., Reiss, Michael, Hsu, Frank J., Berzofsky, Jay A., Lawrence, Donald P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949712/ https://www.ncbi.nlm.nih.gov/pubmed/24618589 http://dx.doi.org/10.1371/journal.pone.0090353 |
Ejemplares similares
-
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients
por: Stevenson, James P, et al.
Publicado: (2013) -
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis
por: Trachtman, Howard, et al.
Publicado: (2011) -
Effects on tumor immunity of anti-TGF-beta with different isoform specificities
por: Terabe, Masaki, et al.
Publicado: (2014) -
Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma.
por: Krasagakis, K., et al.
Publicado: (1998) -
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
por: Vincenti, Flavio, et al.
Publicado: (2017)